default author photo

John Bridgewater

University College London - UCL Cancer Institute

Gower Street

London, WC1E 6BT

United States

SCHOLARLY PAPERS

5

DOWNLOADS

508

TOTAL CITATIONS

2

Scholarly Papers (5)

1.

Long Term Outcomes and Exploratory Analyses of the Randomised Phase 3 BILCAP Study

Number of pages: 46 Posted: 18 Oct 2021
University College London - UCL Cancer Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Leeds Teaching Hospitals NHS Trust, Government of the United Kingdom - Queen Elizabeth Hospital Birmingham, Leeds Teaching Hospitals NHS Trust, affiliation not provided to SSRN, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, Imperial College London - Hammersmith Hospital, Department of Cancer Medicine, affiliation not provided to SSRN, University of Edinburgh - Western General Hospital, Government of the United Kingdom - Weston Park Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Birmingham, NHS Foundation Trust - Cambridge University Hospitals, Government of the United Kingdom - Queen Elizabeth Hospital Birmingham, Royal Free Hospital, Heidelberg University, University of Southampton, Royal Marsden NHS Foundation Trust, affiliation not provided to SSRN, The University of Manchester and University of Southampton
Downloads 167 (451,954)

Abstract:

Loading...

Cholangiocarcinomaadjuvantcapecitabine

2.

Randomised Phase 3 Study of Ivosidenib in IDH1-Mutant Chemotherapy-Refractory Cholangiocarcinoma

Number of pages: 261 Posted: 08 Dec 2019
Memorial Sloan Kettering Cancer Center - Department of Medicine, Hospital Vall d’Hebron, University of Texas at Houston - MD Anderson Cancer Center, University of California, San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, University of Wisconsin-Madison - Carbone Cancer Center, Hospital Universitario 12 de Octubre - Department of Medical Oncology, Harvard University - Dana-Farber Cancer Institute, University of Chicago - Pritzker School of Medicine, Mayo Clinic Hospital - Phoenix, University College London - UCL Cancer Institute, University of Washington - Department of Medicine, Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center, Seoul National University - Department of Internal Medicine, Utah Cancer Specialists, Trinity College (Dublin), Harvard University - Department of Medicine, University of Arizona - Department of Medicine, University of Southern California - Norris Comprehensive Cancer Center, Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., The Christie NHS Foundation Trust - Department of Medical Oncology and Harvard University - Cancer Center
Downloads 145 (511,933)

Abstract:

Loading...

Cholangiocarcinoma; IDH1 mutation; Ivosidenib; Phase 3 study

3.

Standard or High Dose Chemoradiotherapy, with or Without the Protease Inhibitor Nelfinavir, for the Treatment of Locally Advanced Pancreatic Cancer: Efficacy, Safety and Health-Related Quality of Life Outcomes from the Multi-Centre Two Stage Phase 1/Randomised Phase 2 SCALOP-2 Study

Number of pages: 38 Posted: 29 Jan 2024
Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, University of Oxford, University of Oxford, University of Cambridge - Department of Oncology, University College London - UCL Cancer Institute, Manchester Academic Health Sciences Centre - The Christie NHS Foundation Trust, Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, University of Oxford - Nuffield Department of Primary Care Health Sciences, University of Oxford, University of Oxford, Velindre Cancer Centre, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, Imperial College London - Hammersmith Hospital, Department of Cancer Medicine, University of Cambridge, NHS Foundation Trust - Norfolk and Norwich University Hospital, Government of the United Kingdom - Hull University Teaching Hospitals NHS Trust, Coventry University - Coventry University Hospital, Cardiff University - Centre for Trials Research, University of Leeds - Institute of Medical Research, University of Oxford - MRC Oxford Institute for Radiation Oncology, University College London - Department of Medical Physics and Biomedical Engineering and University of Cambridge
Downloads 79 (823,616)

Abstract:

Loading...

Pancreatic cancer, Chemoradiotherapy, Nelfinavir, Dose escalation, Survival, Outcomes, Toxicity, Health-related quality of life

4.

COVID-19 in Cancer Patients on Systemic Anti-Cancer Therapies – Outcomes from CAPITOL (COVID-19 Cancer PatIenTOutcomes in North London)

Number of pages: 43 Posted: 29 Sep 2020
North Middlesex University Hospital, University College London Hospital, University College London Hospital, University College London Hospital, University College London Hospital, University College London Hospital, North Middlesex University Hospital, North Middlesex University Hospital, North Middlesex University Hospital, North Middlesex University Hospital, University College London - UCL Cancer Trials Centre, University College London Hospital, University College London Hospital, University College London Hospital, University College London - UCL Cancer Institute, UCL Cancer Institute and University College London - UCL Cancer Institute
Downloads 65 (933,592)
Citation 1

Abstract:

Loading...

COVID-19; oncology; SARS-CoV-2; coronavirus; cancer; tumour; systemic anticancer treatment; novel coronavirus; SACT; chemotherapy; immunotherapy; hormone therapy; targeted treatment

5.

FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer

Number of pages: 50 Posted: 16 Oct 2020
The Christie NHS Foundation Trust - Department of Medical Oncology, Clatterbridge Cancer Centre, Imperial College London - Hammersmith Hospital, Department of Cancer Medicine, Guy's & St. Thomas’ NHS Foundation Trust - Guy’s Cancer, University Hospitals Birmingham NHS Foundation Trust, University of Nottingham, University Hospitals Bristol - Bristol Haematology and Oncology Centre, Government of the United Kingdom - Royal Free London NHS Foundation Trust, Weston Park Cancer Centre, Government of the United Kingdom - Oxford University Hospitals NHS Foundation Trust, Leeds Teaching Hospitals NHS Trust, Hull University Teaching Hospitals NHS Trust, University of Southampton - University Hospital Southampton NHS Foundation Trust, Maidstone and Tunbridge Wells NHS Trust - Kent Oncology Centre, Government of the United Kingdom - Great Western Hospitals, University of Manchester - Manchester Clinical Trials Unit, University of Manchester - Manchester Clinical Trials Unit, Hampshire Hospitals NHS Foundation Trust, University of Manchester - Department of Health Economics, University College London - UCL Cancer Institute, The Christie NHS Foundation Trust - Department of Medical Oncology and Independent
Downloads 52 (1,052,702)
Citation 1

Abstract:

Loading...

biliary tract, advanced, second-line, chemotherapy, FOLFOX